During a therapeutic ketamine session, the patient usually lies in a comfortable and relaxed setting, often with soft lighting and calming music.
The sensation of everything collapsing to a single point and then rebuilding itself using Mandelbrot fractals can be understood as a subjective description of this altered state of consciousness.
The perception of reality “collapsing” might be attributed to the dissociative effects of ketamine, which can disrupt the brain’s ability to process sensory information and integrate it into a coherent experience. This disruption can create a sense of detachment from the external world and a feeling of unity with a single point as if everything has collapsed into that point.
Mandelbrot fractals are intricate, self-similar patterns found in nature and mathematical structures. The connection between a k-hole experience and Mandelbrot fractals could result from the brain attempting to make sense of the altered sensory input during the dissociative state. Fractals are often associated with psychedelic experiences, representing the brain’s attempt to find structure in the altered, chaotic state.
As the ketamine wears off and the user’s ordinary consciousness begins to return, their brain may attempt to “rebuild” their perception of reality by reintegrating sensory information. This process might be perceived as the world reconstructing itself around the user, possibly following the complex and beautiful patterns of Mandelbrot fractals.
As the ketamine begins to take effect, the person may also experience the following sensations:
- Dissociation: A sense of disconnection from one’s body and the environment. This can feel like floating or observing oneself from a distance. Some people describe it as an “out-of-body” experience.
- Altered perception of time and space: Time may seem to slow down, speed up, or lose meaning altogether. The perception of space may also be distorted, with objects appearing larger or smaller than they are.
- Visual and auditory hallucinations: Some people report seeing geometric patterns, vivid colors, or dream-like scenes. Others may hear sounds or voices that aren’t present.
- Emotional effects: Ketamine can induce euphoria, calm, or introspection. Some people report experiencing a profound sense of inner peace or spiritual connection.
- Cognitive effects: Thoughts may become more abstract, introspective, or philosophical during a ketamine session. People often describe feeling as if they have access to deeper insights about themselves or the world around them.
- Physical sensations: Some users feel weightless, numb, or experiencing tingling sensations in their extremities.
It’s important to remember that therapeutic ketamine sessions are supervised by trained healthcare professionals who monitor the patient’s experience and ensure their safety. The goal of such therapy is to alleviate symptoms of mental health conditions like depression, anxiety, and PTSD, rather than to induce a recreational “k-hole” experience.
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., … & Nemeroff, C. B. (2017). A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry, 74(4), 399-405. doi:10.1001/jamapsychiatry.2017.0080
Feder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., … & Charney, D. S. (2014). Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: A randomized clinical trial. JAMA Psychiatry, 71(6), 681-688. doi:10.1001/jamapsychiatry.2014.62
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018). Side-effects associated with ketamine use in depression: A systematic review. The Lancet Psychiatry, 5(1), 65-78. doi:10.1016/S2215-0366(17)30272-9
Jovaisa, T., Laurinenas, G., Vosylius, S., Šipylaite, J., & Badaras, R. (2006). Effects of ketamine on precipitated opiate withdrawal. Medicina, 42(8), 625-634.
Krupitsky, E. M., & Grinenko, A. Y. (1997). Ketamine psychedelic therapy (KPT): A review of the results of ten years of research. Journal of Psychoactive Drugs, 29(2), 165-183. doi:10.1080/02791072.1997.10400185